7817 Annual Report 2009.qxd - Shire

More documents

Recommendations

Info

32 Shire plc Annual Report and Accounts 2009Board of Directors1 2 3 41Matthew Emmens (58)ChairmanMr Emmens was appointed Non-ExecutiveChairman on June 18, 2008 and has beena member of the Board since March 12, 2003.He is also a member of the Company’sNomination Committee. He was the Company’sChief Executive Officer from March 2003 to June2008. Mr Emmens brings to the Board, amongother things, his operational knowledge of Shireand his wealth of international sales, marketing,integration and operational experience in thepharmaceutical sector. Mr Emmens also servesas Chairman, President and Chief ExecutiveOfficer of Vertex Pharmaceuticals Inc. He is aformer board member of Incyte Corporation.Mr Emmens began his career in internationalpharmaceuticals with Merck & Co, Inc. in 1974,where he held a wide range of sales, marketingand administrative positions. In 1992, he helpedto establish Astra Merck, a joint venture betweenMerck and Astra AB of Sweden, becomingPresident and Chief Executive Officer. In 1999,he joined Merck KGaA and established EMDPharmaceuticals, the company’s globalprescription pharmaceutical business. He waslater based in Darmstadt, Germany as Presidentof Merck KGaA’s US prescription pharmaceuticalbusiness and was a board member. Mr Emmensholds a degree in Business Management fromFairleigh Dickinson University.2Angus Russell (54)Chief Executive OfficerMr Russell was appointed Chief Executive Officeron June 18, 2008 and has been a member ofthe Board since December 13, 1999. He was theCompany’s Chief Financial Officer from December1999 to June 2008. He is also the Chairman of theCompany’s Leadership Team. Mr Russell bringsto his position, among other things, his operationalknowledge of Shire and his extensive finance,risk management, strategic and operationalexperience in the pharmaceutical sector.Mr Russell is a former Non-Executive Director ofthe City of London Investment Trust plc. Between1980 and 1999, he held a number of positionsof increasing responsibility at ICI, Zeneca andAstraZeneca PLC, including Vice President,Corporate Finance at AstraZeneca and GroupTreasurer at Zeneca. Mr Russell is a CharteredAccountant, having qualified with Coopers &Lybrand, and is a Fellow of the Association ofCorporate Treasurers.3Graham Hetherington (51)Chief Financial OfficerMr Hetherington has been the Company’s ChiefFinancial Officer and a member of the Boardsince July 1, 2008. He is also a member of theCompany’s Leadership Team. Mr Hetheringtonbrings to his position, among other things,a broad range of international finance managementand planning, audit, risk management and M&Aexperience. Mr Hetherington most recently heldpositions as the Chief Financial Officer of Bacardiin 2007 and Chief Financial Officer of AlliedDomecq plc from 1999 to 2005. Mr Hetheringtonis a Fellow of the Chartered Institute ofManagement Accountants.4David Kappler (62)Deputy Chairman and Senior IndependentNon-Executive DirectorMr Kappler has been a member of the Company’sBoard since April 5, 2004. He was appointedDeputy Chairman in June 2008 and SeniorIndependent Non-Executive Director in July 2007.He is Chairman of the Company’s NominationCommittee and Audit, Compliance & RiskCommittee. Mr Kappler brings to the Board,among other things, his extensive knowledge andexperience in financial reporting, risk managementand internal financial controls. Mr Kappler alsoserves as the Non-Executive Chairman of PremierFoods plc and as a Non-Executive Directorof Intercontinental Hotels Group plc. Mr Kapplerwas a Director of Camelot Group plc from 1996 to2002 and of HMV Group plc from 2002 to 2006.Mr Kappler retired from Cadbury Schweppes plcin April 2004 after serving as Chief FinancialOfficer since 1995. He worked for the CadburySchweppes group between 1965 and 1984and rejoined the company in 1989 following itsacquisition of the Trebor Group, where he wasFinancial Director. Mr Kappler is a Fellow of theChartered Institute of Management Accountants.5Patrick Langlois (64)Non-Executive DirectorMr Langlois has been a member of the Company’sBoard since November 11, 2005. He is also amember of the Company’s Audit, Compliance &Risk Committee and Remuneration Committee.Mr Langlois brings to the Board, among otherthings, his extensive experience in financialreporting, audit and risk management. Mr Langloisis a Non-Executive Director of Scynexis Inc.,Nanobiotix S.A., Exonhit S.A. and Newron Spa.Mr Langlois previously served as Vice Chairmanof the Management Board of Aventis S.A.,Strasbourg, having been Group Executive VicePresident and Chief Financial Officer for severalyears. He also spent many years in seniorfinancial roles with the Rhône-Poulenc Group,including three years as a member of theExecutive Committee and Chief Financial Officer.Mr Langlois holds a PhD in Economics anda diploma in banking studies.
Shire plc Annual Report and Accounts 2009335 6 7 86Dr Jeffrey Leiden (54)Vice Chairman and Non-Executive DirectorDr Leiden has been a member of the Company’sBoard since January 1, 2007, and Vice Chairmansince April 2009. He is a member of theCompany’s Remuneration Committee andNomination Committee and Chairman of theCompany’s Science & Technology Committee.Dr Leiden brings to the Board, among otherthings, his extensive operational experience inpharmaceutical companies and his operationaland scientific experience in clinical research,development and registration. Dr Leiden is alsoa Managing Director at Clarus Ventures LLC,Chairman of the Board of Directors of TyRxPharma, Inc., Lycera Corporation and VariationBiotechnologies Inc., and a member of the Boardof Directors of Biolex Therapeutics Inc., andVertex Pharmaceuticals Inc. Dr Leiden servedas President and Chief Operating Officer,Pharmaceutical Products Group and ChiefScientific Officer at Abbott Laboratories from2001 to 2006; during this time he was also amember of the Boards of Directors of Abbott andTAP Pharmaceutical Products, Inc. Prior to joiningAbbott, Dr Leiden served as the Elkan R. BloutProfessor of Biological Sciences, Harvard Schoolof Public Health and Professor of Medicine,Harvard Medical School. Previously, he was theFrederick H. Rawson Professor of Medicine andPathology and Chief of the Section of Cardiologyat the University of Chicago. Dr Leiden was afounder of Cardiogene, Inc., a biotechnologycompany specializing in cardiovascular genetherapy. Dr Leiden earned a bachelor’s degree inbiological sciences, a doctorate in virology and amedical degree, all from the University of Chicago.He is a Fellow of the American Academy of Artsand Sciences and an elected member of theInstitute of Medicine of the National Academyof Sciences. Dr Leiden is currently a ManagingDirector at Clarus Ventures LLC.7Kate Nealon (56)Non-Executive DirectorMs Nealon has been a member of the Company’sBoard since July 27, 2006. She is Chairmanof the Company’s Remuneration Committee andalso a member of the Audit, Compliance & RiskCommittee. Ms Nealon brings to the Board,among other things, her extensive global legal,compliance and risk management experiencegained through roles held in multinationalcompanies. Ms Nealon is a Non-ExecutiveDirector of Cable & Wireless plc and a formerNon-Executive Director of HBOS plc. She is alsoa Senior Associate at the Judge BusinessSchool at Cambridge University. Ms Nealon waspreviously Group Head of Legal & Complianceat Standard Chartered plc until 2004. She isa US qualified lawyer and spent several yearsin her early career practising law in New York.8David Stout (55)Non-Executive DirectorMr David Stout joined the Board as a Non-Executive Director with effect from October 31,2009 and is a member of the Audit, Compliance& Risk Committee. Mr Stout brings to the Board,among other things, extensive internationalsales, marketing, operational and supply chainexperience gained in the pharmaceutical sector.Mr Stout also holds directorships at AllosTherapeutics, Inc, Jabil Circuit, Inc. and Airgas Inc.Most recently he was President, PharmaceuticalOperations at GSK. In this position he hadresponsibility for pharmaceutical operationsin the United States, Europe, Japan and all otherInternational Markets. Mr Stout was alsoresponsible for global manufacturing and globalBiologics (vaccines) at GSK. Prior to that, he wasPresident of GSK’s US Pharmaceuticals Businessand before that SmithKline Beecham’s NorthAmerican Pharmaceuticals Business. Beforejoining SmithKline Beecham, Mr Stout workedfor many years at Schering-Plough.Former Non-Executive DirectorsDr Barry Price (66)Non-Executive DirectorDr Price was a member of the Company’s Board fromJanuary 16, 1996 until his retirement from the Board onJanuary 24, 2010. He was a member of the Company’sNomination Committee and Science & Technology Committeeuntil October 2009 and January 2010 respectively. Dr Pricebrought to the Board, among other things, his wealth ofexperience in the operational and scientific aspects of clinicalresearch and development. He serves as Chairman ofAntisoma plc and Summit Corporation plc. In recent yearshe has held directorships at Chiroscience plc, CelltechGroup plc, Pharmagene plc and BioWisdom Limited. Dr Priceworked for GSK for 28 years, where he held positions ofincreasing responsibility with that company’s research group.David Mott (44)Non-Executive DirectorMr Mott was a member of the Company’s Board fromOctober 31, 2007 to October 30, 2009. He was a memberof the Company’s Audit, Compliance & Risk Committeeuntil October 2009. Mr Mott joined venture capital firm NewEnterprise Associates (‘NEA’) in September 2008 as a GeneralPartner focused on biopharmaceutical investments. Priorto joining NEA, Mr Mott was President and Chief ExecutiveOfficer of MedImmune Inc., a subsidiary of AstraZeneca PLC,and Executive Vice President of AstraZeneca. Formerly, hewas a Vice President in the Health Care Investment BankingGroup at Smith Barney, Harris Upham & Co. Inc. He is amember of the board of Rib-x Pharmaceuticals Inc. and alsoa former board member of Ambit Biosciences and ConceptisTechnologies. Mr Mott holds a bachelor’s degree ineconomics and government from Dartmouth College.Dr Michael Rosenblatt (62)Non-Executive DirectorDr Rosenblatt was a member of the Company’s Board fromApril 24, 2008 to December 23, 2009. He was a memberof the Company’s Nomination Committee, RemunerationCommittee and Science & Technology Committee untilDecember 23, 2009. Dr Rosenblatt is the Dean of TuftsUniversity School of Medicine, Boston, Massachusetts.He was previously Professor of Medicine at Harvard MedicalSchool and has served in senior research positions at theBeth Israel Deaconess Medical Center in Boston. He was thefounding director of the Carl J. Shapiro Institute for Educationand Research at Harvard Medical School and Beth IsraelDeaconess Medical Center. In addition, Dr Rosenblatt hasserved as Director of the Harvard-MIT Division of HealthSciences and Technology and as Senior Vice President forResearch at Merck Sharp & Dohme Research Laboratorieswhere he headed a worldwide development team as wellas directing drug discovery efforts in the United States,Japan and Italy. He also headed Merck Research’s worldwideUniversity and Industry Relations Department. He is agraduate of Columbia University and gained his medicalqualification at Harvard Medical School.
Page 1: Shire plc Annual Report and Account
Page 4 and 5: 2 Shire plc Annual Report and Accou
Page 12 and 13: 10 Shire plc Annual Report and Acco
Page 84 and 85:
82 Shire plc Annual Report and Acco
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
100 Shire plc Annual Report and Acc
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148:
Shire plc5 RiverwalkCitywest Busine
show all

7817 Annual Report 2009.qxd - Shire

Create successful ePaper yourself

Delete template?

Save as template?